Semaglutide Tablets 2026: Rybelsus, Oral Wegovy & Compounded Options
Updated May 6, 2026 · By Chad Simpson
How this page is reviewed
Editorially reviewed by GLP1CompareHub Editorial Team. We are an independent affiliate publisher — we are not licensed medical providers and this site does not deliver medical advice. Every claim on this page is sourced to a verifiable origin (peer-reviewed study, FDA documentation, live brand-site crawl, or our Katalys partner dashboard).
Affiliate disclosure: We earn a commission when you sign up with a provider through our links — at no extra cost to you. We do not rank providers by what they pay us; we rank by patient fit. Full disclosure. Read our methodology · medical disclaimer.
Quick Answer
The only FDA-approved semaglutide tablet is Rybelsus (14mg) — and it is approved only for type 2 diabetes, not weight loss or obesity. An oral Wegovy pill (50mg) for obesity is in late-stage development and FDA approval is pending as of May 2026. Compounded oral semaglutide tablets exist but lack the SNAC absorption technology that makes Rybelsus work, limiting bioavailability to ~1%.
Rybelsus: The Only Approved Semaglutide Tablet
Rybelsus is Novo Nordisk's oral semaglutide tablet, FDA-approved in September 2019 for adults with type 2 diabetes. It is the same active compound as Ozempic and Wegovy — semaglutide — but reformulated for oral use using proprietary SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) absorption technology.
Rybelsus Dosing Protocol
- 3mg daily for the first 30 days (dose initiation)
- 7mg daily for at least 30 days (maintenance)
- 14mg daily if additional glycemic control needed (maximum dose)
Critical Administration Rule
Take Rybelsus on an empty stomach with no more than 4 oz (120 mL) of plain water. Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications. Food, large amounts of water, or other drinks can reduce absorption by up to 50%. The SNAC absorber requires a very specific gastric environment to work.
Despite being the same molecule as Ozempic, Rybelsus at 14mg produces lower peak plasma concentrations than injectable semaglutide. In trials, Rybelsus reduced HbA1c by ~1.4% and produced modest weight loss (~4.4 lbs at 14mg). It is not approved for obesity management and the clinical weight loss seen is substantially less than what Wegovy injectable produces (~15% of body weight).
Oral Wegovy (50mg): The Obesity Pill in the Pipeline
Novo Nordisk has been developing a higher-dose oral semaglutide formulation specifically for obesity. The OASIS-1 phase 3 trial enrolled 667 adults with obesity (BMI ≥30) and no diabetes. Key results at 68 weeks:
The 15.1% weight loss at 68 weeks approaches (but doesn't fully match) the ~17.4% seen with weekly injectable Wegovy at 68 weeks in STEP-1. The oral pill uses the same SNAC technology as Rybelsus, just at a higher dose and optimized for obesity indication.
FDA Approval Status (May 2026)
Novo Nordisk has submitted the oral semaglutide 50mg obesity indication for FDA review. No confirmed approval date has been announced as of May 2026. When approved, it will likely be branded as oral Wegovy or a variant name.
Compounded Oral Semaglutide: What's Available and What to Know
Compounded Oral Tablets
Some 503A compounding pharmacies prepare oral semaglutide tablets or capsules. The critical limitation: these formulations do not contain SNAC. Without SNAC, semaglutide's oral bioavailability is approximately 1% — meaning 99% of the dose is degraded in the GI tract before reaching systemic circulation. This is not a compounding quality issue; it is a fundamental pharmacokinetics problem. The SNAC technology in Rybelsus is proprietary to Novo Nordisk and is what makes oral semaglutide work at all.
Compounded semaglutide oral tablets without SNAC are not recommended as a clinical alternative to injectable semaglutide. At ~1% bioavailability, even a high-dose compounded tablet delivers negligible active drug.
Compounded Sublingual Semaglutide
Sublingual (under-the-tongue) semaglutide drops bypass the GI tract by absorbing through the oral mucosa. Some telehealth providers claim 10–30% bioavailability with sublingual formulations — significantly better than oral tablets without SNAC. However, there are no published randomized controlled trials directly comparing sublingual compounded semaglutide to injectable semaglutide for weight loss outcomes. The absorption estimate comes from pharmacokinetic modeling, not head-to-head outcome data.
TMates offers a confirmed sublingual semaglutide formulation. If you need an injection-free semaglutide option today and can't wait for oral Wegovy approval, sublingual is the most evidence-adjacent non-injectable route currently available.
Semaglutide Oral Options Compared
| Option | FDA Status | Indication | Bioavailability | Est. Price/Mo |
|---|---|---|---|---|
| Rybelsus 14mg (brand) | FDA Approved | Type 2 Diabetes only | ~1% (SNAC-enabled ~0.4–1%) | $800–$1,000 (retail) |
| Oral Wegovy 50mg (pipeline) | Pending FDA | Obesity (when approved) | ~1% (SNAC-enabled) | TBD |
| Compounded oral tablet | Not FDA Approved | Off-label / physician Rx | ~1% (no SNAC) | $100–$200 |
| Compounded sublingual | Not FDA Approved | Off-label / physician Rx | ~10–30% (claimed, no RCT) | $100–$200 |
| Compounded injectable | Not FDA Approved | Off-label / physician Rx | ~100% (subcutaneous) | $99–$250 |
Prices are estimates as of May 2026. Bioavailability figures from published pharmacokinetic literature and provider claims.
Practical Recommendation: What to Do in May 2026
If you want semaglutide for weight loss and prefer not to inject, your decision depends on your timeline and risk tolerance. Here's what's available from telehealth providers now:
Strut Health
Best ValueCompounded injectable semaglutide starting at $99/month. Not a tablet, but if efficacy is your priority and the needle is the main barrier — Strut is the most affordable clinical-grade entry point. Physician-supervised, includes titration support.
See Strut Health PlansTMates
Verified on brand site Invalid DateOffers confirmed sublingual semaglutide — the closest to a true oral option currently available outside of Rybelsus. If avoiding injections is non-negotiable, TMates is the provider to start with for sublingual.
See TMates PlansEden Health
Verified on brand site Invalid DateCompounded injectable semaglutide with a comprehensive physician-supervised program. Higher price point but includes more clinical touchpoints.
See Eden PlansEmbody
Verified on brand site Invalid DateOffers GLP-1 gum as an adjunct option alongside standard compounded semaglutide programs. Introductory pricing makes it worth evaluating alongside TMates for non-injectable preferences.
See Embody PlansFrequently Asked Questions
Is there a semaglutide pill for weight loss?
As of May 2026, no. The only FDA-approved oral semaglutide is Rybelsus (14mg), which is approved for type 2 diabetes — not obesity. Oral Wegovy (50mg) for obesity is in late-stage development with FDA approval pending.
What is Rybelsus and is it the same as Ozempic?
Rybelsus and Ozempic both contain semaglutide, but Rybelsus is a daily oral tablet and Ozempic is a weekly injection. Both are approved for type 2 diabetes. Wegovy is the higher-dose weekly injectable approved for obesity.
Why does Rybelsus have to be taken on an empty stomach?
Rybelsus uses SNAC technology to penetrate the gastric mucosa. Food and excess water disrupt the gastric pH environment that SNAC requires, reducing absorption by up to 50%. You must take it with no more than 4oz of water and wait 30 minutes before eating anything.
Can you get compounded oral semaglutide tablets?
Yes, some 503A pharmacies compound oral semaglutide. However, without SNAC technology, bioavailability is approximately 1% — making them clinically insufficient compared to injectable. Compounded sublingual drops offer better (though unproven by RCT) absorption.
When will the oral Wegovy pill be available?
Novo Nordisk's 50mg oral semaglutide for obesity has completed the OASIS-1 phase 3 trial (~15.1% weight loss at 68 weeks). FDA approval is pending as of May 2026 with no confirmed date.
What is the best option for semaglutide if I cannot inject?
Your best non-injectable option today is sublingual compounded semaglutide (TMates offers this). For the highest-efficacy option regardless of route, compounded injectable from Strut Health at $99/mo is the strongest clinical choice. Wait for oral Wegovy FDA approval if you want an evidence-backed pill.
Related Articles
Related Guides
Continue your research with these related independent reviews.